Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900658 | 0.86 | SMN1; SMN2 (0.43) | KLKB1METAP2CHRNA7ALDH1A1MAPT | |
| SCHEMBL1111565 | 0.81 | KLKB1 (0.46) | KLKB1METAP2CHRNA7ALDH1A1MAPT | |
| SCHEMBL1111550 | 0.81 | ALDH1A1 (0.44) | KLKB1CHRNA7ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1111625 | 0.80 | ALDH1A1 (0.44) | KLKB1METAP2CHRNA7ALDH1A1MAPT | |
| SCHEMBL12958860 | 0.77 | ALDH1A1 (0.48) | KLKB1ALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL12900635 | 0.74 | ALDH1A1 (0.49) | KLKB1CHRNA7ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12804153 | 0.74 | SMN1; SMN2 (0.57) | KLKB1METAP2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8000039 | 0.74 | POLB (0.46) | KLKB1ALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL8002663 | 0.73 | ALDH1A1 (0.45) | KLKB1ALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL1271523 | 0.73 | CHRNA7 (0.36) | KLKB1METAP2CHRNA7ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| CN-102066356-A | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2011-05-18 | — | — | CN | claimed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | claimed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | claimed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | claimed |
| CN-102066356-B | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2014-06-11 | — | — | CN | disclosed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| CN-102066356-A | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2011-05-18 | — | — | CN | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | CHRNA7, CHRNA5, CHRNA6 | CHRM2 24/4885CHRM1 20/4885CHRM3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.